The original patent won on October 18, 2018 covered some coPrimer molecule programs, which demonstrated the functionality of molecular diagnostic tests through the polymerrasa chain reaction (“PCR”) particularly minimizing the effects of positive false testing, and their use. pcRArray but not the molecule itself. The additional patent covers the physical design of the CoPrimer molecule, with broader claims and adds all the configurations of a molecule with that design.
The CoPrimer generation is the platform used in the company’s flagship COVID-19 verification kits, which have been implemented abroad and in the United States. The CoPrimer generation has also been authorized for programs through LGC, Biosearch Technologies, a foreign leader in the long-life sciences sector, with a presence in more than two hundred countries.